- Volume 22 Issue 3
DOI QR Code
A carboxymethyl dextran-based polymeric conjugate as the antigen carrier for cancer immunotherapy
- Shin, Jung Min (School of Chemical Engineering, Sungkyunkwan University) ;
- Song, Seok Ho (School of Chemical Engineering, Sungkyunkwan University) ;
- Rao, N. Vijayakameswara (School of Chemical Engineering, Sungkyunkwan University) ;
- Lee, Eun Sook (Department of Health Science and Technology, SAIHST, Sungkyunkwan University) ;
- Ko, Hyewon (Department of Health Science and Technology, SAIHST, Sungkyunkwan University) ;
- Park, Jae Hyung (School of Chemical Engineering, Sungkyunkwan University)
- Received : 2018.05.23
- Accepted : 2018.07.30
- Published : 2018.09.30
Background: Antigen-specific cytotoxic T lymphocytes (CTLs), which eliminate target cells bearing antigenic peptides presented by surface major histocompatibility complex (MHC) class I molecules, play a key role in cancer immunotherapy. However, the majority of tumors are not immunologically rejected since they express self-antigens which are not recognized by CTLs as foreign. To foreignize these tumors for CTL-mediated immunological rejection, it is essential to develop carriers that can effectively deliver foreign antigens to cancer cells. Methods: A polymeric conjugate, composed of a carboxymethyl dextran (CMD) as the backbone and ovalbumin (OVA) as a model foreign antigen, was prepared to investigate its potential as the antigen carrier for cancer immunotherapy. Results: An in vitro cellular uptake study showed that the conjugate was successfully taken up by TC-1 cervical cancer cells. When CMD-OVA was systemically administered to tumor-bearing mice, the strong fluorescence signal was observed at the tumor site over the whole period of time period, suggesting high tumor targetability of the conjugate. Compared to free OVA, CMD-OVA induced significantly higher antigen presentation at the tumor site. Conclusions: The CMD-OVA conjugate can effectively deliver the antigen to the tumor site, implying its high potential as the antigen carrier for cancer immunotherapy.
Supported by : National Research Foundation of Korea (NRF)
- Friedl P, den Boer AT, Gunzer M. Tuning immune responses: diversity and adaptation of the immunological synapse. Nat Rev Immunol. 2005;5:532.
- Kang TH, Lee JH, Song CK, Han HD, Shin BC, Pai SI, Hung C-F, Trimble C, Lim J-S, Kim TW, Wu TC. Epigallocatechin-3-Gallate enhances CD8(+) T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res. 2007;67:802-11.
- Jondal M, Schirmbeck R, Reimann J. MHC class I-restricted CTL responses to exogenous antigens. Immunity. 1996;5:295-302.
- Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2017;15:31.
- Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2017;15:47.
- Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348:62-8.
- Lee Y-H, Yoon HY, Shin JM, Saravanakumar G, Noh KH, Song K-H, Jeon J-H, Kim D-W, Lee K-M, Kim K, Kwon IC, Park JH, Kim TW. A polymeric conjugate foreignizing tumor cells for targeted immunotherapy in vivo. J Control Release. 2015;199:98-105.
- Shin JM, Oh SJ, Kwon S, Deepagan VG, Lee M, Song SH, Lee H-J, Kim S, Song K-H, Kim TW, Park JH. A PEGylated hyaluronic acid conjugate for targeted cancer immunotherapy. J Control Release. 2017;267:181-90.
- Bourzac K. Nanotechnology: carrying drugs. Nature. 2012;491:S58.
- Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271-84.
- Rao N V, Dinda H, Ganivada MN, Das Sarma J, Shunmugam R. Efficient approach to prepare multiple chemotherapeutic agent conjugated nanocarrier. Chemical Communications. 50((2014)):13540-3.
- Rao N V, Ganivada MN, Sarkar S, Dinda H, Chatterjee K, Dalui T, Das Sarma J, Shunmugam R. Magnetic Norbornene Polymer as Multiresponsive Nanocarrier for Site Specific Cancer Therapy. Bioconjug Chem. 25((2014)):276-85.
- Shin JM, Hwang SR, Heo R, Saravanakumar G, Park JH. Amphiphilic hyaluronic acid derivative with the bioreducible bond: synthesis and its implication for intracellular drug delivery. Polym Degrad Stab. 2014;109:398-404.
- J.M. Shin, S.H. Kim, T. Thambi, D.G. You, J. Jeon, J.O. Lee, B.Y. Chung, D.G. Jo, J.H. Park, A hyaluronic acid-methotrexate conjugate for targeted therapy of rheumatoid arthritis, Chemical communications (Cambridge, England), 50(2014) 7632-7635.
- Thambi T, You DG, Han HS, Deepagan VG, Jeon SM, Suh YD, Choi KY, Kim K, Kwon IC, Yi GR, Lee JY, Lee DS, Park JH. Bioreducible Carboxymethyl dextran nanoparticles for tumor-targeted drug delivery. Advanced Healthcare Materials. 2014;3:1829-38.
- Wang Z-H, Zhu Y, Chai M-Y, Yang W-T, Xu F-J. Biocleavable comb-shaped gene carriers from dextran backbones with bioreducible ATRP initiation sites. Biomaterials. 2012;33:1873-83.
- Son S, Rao NV, Ko H, Shin S, Jeon J, Han HS, Nguyen VQ, Thambi T, Suh YD, Park JH. Carboxymethyl dextran-based hypoxia-responsive nanoparticles for doxorubicin delivery. Int J Biol Macromol. 2018;110:399-405.
- Okuno S, Harada M, Yano T, Yano S, Kiuchi S, Tsuda N, Sakamura Y, Imai J, Kawaguchi T, Tsujihara K. Complete regression of Xenografted human carcinomas by Camptothecin analogue-Carboxymethyl dextran conjugate (T-0128). Cancer Res. 2000;60:2988-95.
- Gaowa A, Horibe T, Kohno M, Tabata Y, Harada H, Hiraoka M, Kawakami K. Enhancement of anti-tumor activity of hybrid peptide in conjugation with carboxymethyl dextran via disulfide linkers. Eur J Pharm Biopharm. 2015;92:228-36.
- Alconcel SN, Baas AS, Maynard HD. FDA-approved poly (ethylene glycol)-protein conjugate drugs. Polym Chem. 2011;2:1442-8.
- Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33:2373-87.
- Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. Ipilimumab: Nature Publishing Group; 2011.
- Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra225.
- Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217.